首页 > 市场调查报告书 > 製药

癌症

北美胶质瘤治疗市场预测至 2030 年 - 区域分析 - 按疾病、治疗类型、等级和最终用户

市场调查报告书

商品编码

1452589

北美胶质瘤治疗市场预测至 2030 年 - 区域分析 - 按疾病、治疗类型、等级和最终用户

North America Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 92 Pages | 订单完成后即时交付

价格

简介目录图表

北美胶质瘤治疗市场预计将从2022年的21.7988亿美元成长到2030年的43.7738亿美元。预计2022年至2030年CAGR为9.1%。

地区和州政府为患者提供治疗机会的倡议推动了北美神经胶质瘤治疗市场

2021 年 12 月，患者访问网络 (PAN) 基金会和美国脑肿瘤协会宣布建立新的合作伙伴关係，透过为患者提供每年高达 1,600 美元的服务财政援助来支持胶质母细胞瘤患者。此外，北美神经胶质瘤治疗市场的领先公司专注于推出新产品和开发现有产品。 2020年12月，CNS Pharmaceuticals, Inc.宣布美国食品药物管理局授权使用贝柔比星治疗多形性胶质母细胞瘤患者。此外，美国食品药物管理局于 2021 年 8 月将 Lantern Pharma Inc. 的 LP-184 指定为孤儿药，用于治疗多形性胶质母细胞瘤和其他恶性胶质瘤。 2020 年5 月还举办了一场关于多形性胶质母细胞瘤(GBM) 以及Lantern Pharma 的LP-184 治疗GBM 和其他类型脑癌的潜力的网路研讨会。因此，区域和州政府努力为患者提供获取途径新疗法加速了北美神经胶质瘤治疗市场的成长。

北美神经胶质瘤治疗市场概述

北美的神经胶质瘤治疗市场分为美国、加拿大和墨西哥；美国在该地区占有最大的市场份额。市场成长主要归因于脑肿瘤病例的增加、技术的快速创新和医疗基础设施的发展。根据美国脑瘤协会 2023 年发布的报告，胶质母细胞瘤是最致命、最复杂且难以治疗的癌症之一。预计到 2023 年，将有超过 14,490 名美国人被诊断为 GBM，约占所有原发性恶性脑瘤的 50.1%。北美市场的知名企业正在专注于各种成长策略，例如合併、收购、合作伙伴关係和新产品发布，以扩大其地理影响力并增强其产品供应。例如，总部位于瑞典的 Elekta 公司与 GE Healthcare 合作，在放射肿瘤学领域带来创新。透过此次合作，医院将为需要放射治疗的癌症患者提供广泛的治疗。

美国在北美神经胶质瘤治疗市场中占有重要份额。这个国家的市场成长主要是由脑肿瘤盛行率的增加、神经胶质瘤治疗技术的不断进步以及吸烟者数量的增加所推动的。根据美国临床肿瘤学会 (ASCO) 的数据，预计到 2022 年，美国将有近 24,530 名成年人（13,840 名男性和 10,690 名女性）被诊断出患有原发性脑部和脊髓癌性肿瘤。脑肿瘤是原发性中枢神经系统（CNS）恶性肿瘤，占所有原发性中枢神经系统病例的85-90%。随着脑肿瘤病例数量的增加，对更快治疗的需求也在增加。根据加拿大脑瘤登记处的数据，加拿大每 10 万人中就有 4 人患有胶质母细胞瘤，每年有近 1,000 名加拿大人被诊断出患有胶质母细胞瘤。胶质母细胞瘤治疗市场参与者正在采用各种有机和无机策略来在加拿大市场取得成功。 2021 年 2 月，Medexus Pharmaceuticals Inc. 启动了 Gleolan 在加拿大的商业上市，此前该药物仅根据加拿大卫生部特别准入计划进行分销。 Gleolan 是一种显影剂，可导致高级神经胶质瘤（恶性且快速进展的脑肿瘤）在蓝光下发出萤光，帮助神经外科医生更好地观察这些神经胶质瘤，以便完全切除。目前加拿大没有其他核准的光学影像剂可用于在神经胶质瘤手术期间可视化恶性组织。此外，发展医疗基础设施、增加研发投资以及治疗程序的改进预计将在预测期内推动墨西哥的北美神经胶质瘤治疗市场。

北美胶质瘤治疗市场收入及 2030 年预测（百万美元）

北美胶质瘤治疗市场细分

北美神经胶质瘤治疗市场按疾病、治疗类型、等级、最终用户和国家细分。

根据疾病，北美神经胶质瘤治疗市场分为星状细胞瘤、少突星状细胞瘤和少突胶质细胞瘤。 2022 年，星状细胞瘤细分市场占据北美神经胶质瘤治疗市场的最大份额。

依治疗类型，北美神经胶质瘤治疗市场分为手术、化疗、放射治疗等。 2022年，手术细分市场占据北美神经胶质瘤治疗市场的最大份额。

根据级别，北美神经胶质瘤治疗市场分为低级别和高级别。 2022 年，高层级细分市场在北美神经胶质瘤治疗市场中占有更大份额。

根据最终用户，北美神经胶质瘤治疗市场分为医院和诊所以及门诊手术中心。 2022 年，医院和诊所部门在北美神经胶质瘤治疗市场中占有更大份额。

依国家/地区划分，北美神经胶质瘤治疗市场分为德国、美国、加拿大和墨西哥。 2022年，美国主导北美神经胶质瘤治疗市场。

Amgen Inc、Amneal Pharmaceuticals Inc、Arbor Pharmaceuticals LLC、Biocon Ltd、F. Hoffmann-La Roche Ltd、Karyopharm Therapeutics Inc、Merck & Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd 和 Teva Pharmaceutical Industries Ltd 是一些领先公司经营北美神经神经系统胶质瘤治疗市场。

In December 2021, the Patient Access Network (PAN) Foundation and the American Brain Tumor Association announced a new partnership to support persons with glioblastoma by offering financial assistance for services worth up to US$ 1,600 per year for patients. Moreover, leading companies in the North America glioma treatment market focus on launching new products and developing existing ones. In December 2020, CNS Pharmaceuticals, Inc. announced the authorization of the use of berubicin by the Food and Medication Administration to treat patients with glioblastoma multiforme. In addition, the Food and Medication Administration designated LP-184 by Lantern Pharma Inc. as an orphan medication in August 2021 for treating glioblastoma multiforme and other malignant gliomas. A webinar on glioblastoma multiforme (GBM) and the potential of Lantern Pharma\'s LP-184 for treating GBM and other types of brain cancer was also held in May 2020. Thus, efforts made by regional and state governments to provide patients with access to novel treatments accelerate the North America glioma treatment market growth.

North America Glioma Treatment Market Overview

The North America glioma treatment market in North America is segmented into the US, Canada, and Mexico; the US holds the largest share of the market in this region. The market growth is mainly attributed to the increasing brain tumor cases, rapid technological innovations, and developing healthcare infrastructure. According to a report published by the National Brain Tumor Society in 2023, glioblastoma is one of the deadliest, most complex, and treatment-resistant forms of cancer. Over 14,490 Americans are projected to receive a GBM diagnosis in 2023, accounting for ~50.1% of all primary malignant brain tumors. Prominent players in the North American market are focusing on various growth strategies such as mergers, acquisitions, partnerships, and new product launches to expand their geographic presence and enhance their product offerings. For instance, Elekta, a Sweden-based company, collaborated with GE Healthcare to bring innovations in the field of radiation oncology. Through this collaboration, hospitals would be provided with a wide range of treatments for cancer patients requiring radiation therapy.

The US holds a significant share of the North America glioma treatment market in North America. The market growth in this country is primarily driven by the increasing prevalence of brain tumor, growing technological advancements in glioma treatment, and the rising number of smokers. According to the American Society of Clinical Oncology (ASCO), in 2022, nearly 24,530 adults (13,840 men and 10,690 women) are estimated to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US. Brain tumors are the primary central nervous system (CNS) malignancies, which account for 85-90% of all primary CNS cases. The demand for faster treatment is growing with the rising number of brain tumor cases. According to the Brain Tumor Registry of Canada, 4 out of 100,000 people in Canada suffer from glioblastoma, and nearly 1,000 Canadians are diagnosed with glioblastoma each year. The glioblastoma treatment market players are adopting various organic and inorganic strategies to succeed in the Canadian market. In February 2021, Medexus Pharmaceuticals Inc. initiated the commercial launch of Gleolan in Canada, which was previously only distributed under the Health Canada special access program. Gleolan is an imaging agent that causes high-grade gliomas (malignant and rapidly progressing brain tumors) to fluoresce under blue light, helping neurosurgeons better visualize these gliomas for complete removal. There are currently no other approved optical imaging agents in Canada for visualizing malignant tissues during glioma surgery. Further, developing healthcare infrastructure, increasing investments in research & development, and improvements in treatment procedures are anticipated to drive the North America glioma treatment market in Mexico during the forecast period.

North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Glioma Treatment Market Segmentation

The North America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the North America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the North America glioma treatment market in 2022.

Based on treatment type, the North America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the North America glioma treatment market in 2022.

Based on grade, the North America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the North America glioma treatment market in 2022.

Based on end user, the North America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the North America glioma treatment market in 2022.

Based on country, the North America glioma treatment market is segmented into Germany, the US, Canada, and Mexico. The US dominated the North America glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America glioma treatment market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - North America Market Analysis

5.1 North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 North America Glioma Treatment Market, by Country
  - 10.1.1.1 US
    - 10.1.1.1.1 US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 US: North America Glioma Treatment Market, by Disease
    - 10.1.1.1.3 US: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 US: North America Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 US: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 US: North America Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 US: North America Glioma Treatment Market, by End User
  - 10.1.1.2 Canada
    - 10.1.1.2.1 Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Canada: North America Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Canada: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Canada: North America Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Canada: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Canada: North America Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Canada: North America Glioma Treatment Market, by End User
  - 10.1.1.3 Mexico
    - 10.1.1.3.1 Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 Mexico: North America Glioma Treatment Market, by Disease
    - 10.1.1.3.3 Mexico: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 Mexico: North America Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 Mexico: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 Mexico: North America Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 Mexico: North America Glioma Treatment Market, by End User

11. North America Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Arbor Pharmaceuticals LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Merck & Co Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Sun Pharmaceutical Industries Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Amgen Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Pfizer Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Amneal Pharmaceuticals Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Karyopharm Therapeutics Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Biocon Ltd
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Glioma Treatment Market Segmentation
Table 2. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 3. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 4. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 6. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 8. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 9. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 10. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 13. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 14. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 15. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 16. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 20. Organic Developments Done By Companies
Table 21. Inorganic Developments Done By Companies
Table 22. Glossary of Terms, North America glioma treatment market

List Of Figures

Figure 1. North America Glioma Treatment Market Segmentation, By Country
Figure 2. North America Glioma Treatment Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Glioma Treatment Market, 2022 ($Mn)
Figure 25. North America Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Growth Strategies Done by the Companies in the Market, (%)